Warning: fopen(/home/virtual/enm-kes/journal/upload/ip_log/ip_log_2025-02.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 100 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 101
1Department of Endocrinology and Diabetes, Nagoya University Hospital, Nagoya, Japan
2Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan
Copyright © 2021 Korean Endocrine Society
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICTS OF INTEREST
Shintaro Iwama is a consultant/advisory board member on endocrinological adverse events for Ono Pharmaceutical Company, Bristol–Myers Squibb, and Chugai Pharmaceutical Co. Ltd., and received personal fees from Ono Pharmaceutical Company, Bristol–Myers Squibb, Chugai Pharmaceutical Co., Ltd., and MSD K.K outside of this study. Hiroshi Arima received grants from Ono Pharmaceutical Company, MSD K.K., and Chugai Pharmaceutical Co. Ltd., as well as personal fees from Ono Pharmaceutical Company, Bristol–Myers Squibb, and MSD K.K outside of this study.
Type of endocrine irAE | Clinical type | At baselinea | At onsetb |
---|---|---|---|
Pituitary dysfunction | Hypophysitis | Unknown | APA |
IAD | Unknown | APA | |
Primary adrenal insufficiency | Unknown | 21-Hydroxylase Ab | |
Thyroid dysfunction | Destructive thyroiditis | TgAb, TPOAb | TgAb, TPOAb |
Hypothyroidism | TgAb, TPOAb | TgAb, TPOAb | |
Hyperthyroidism | Unknown | TRAb | |
Hypoparathyroidism | Unknown | Anti-CaSR Ab | |
Type 1 diabetes mellitus | GADAb, IA-2Ab, ZnT8Ab | GADAb, IA-2Ab, ZnT8Ab, IAA, ICA |
irAE, immune-related adverse event; APA, anti-pituitary antibody; IAD, isolated adrenocorticotropic hormone (ACTH) deficiency; 21-hydroxylase Ab, autoantibody against 21-hydroxylase; TgAb, anti-thyroglobulin antibody; TPOAb, anti-thyroid peroxidase antibody; TRAb, anti-TSH receptor antibody; Anti-CaSR Ab, anti-calcium-sensing receptor antibody; GADAb, anti-glutamic acid decarboxylase antibody; IA-2Ab, anti-islet antigen 2 antibody; ZnT8Ab, anti-zinc transporter 8 antibody; IAA, insulin autoantibody; ICA, islet cell antibody.
a Autoantibodies detected before the initiation of immune checkpoint inhibitors;
b Autoantibodies detected at the onset of endocrine irAEs.
Type of endocrine irAE | Clinical type | At baseline |
At onset |
---|---|---|---|
Pituitary dysfunction | Hypophysitis | Unknown | APA |
IAD | Unknown | APA | |
Primary adrenal insufficiency | Unknown | 21-Hydroxylase Ab | |
Thyroid dysfunction | Destructive thyroiditis | TgAb, TPOAb | TgAb, TPOAb |
Hypothyroidism | TgAb, TPOAb | TgAb, TPOAb | |
Hyperthyroidism | Unknown | TRAb | |
Hypoparathyroidism | Unknown | Anti-CaSR Ab | |
Type 1 diabetes mellitus | GADAb, IA-2Ab, ZnT8Ab | GADAb, IA-2Ab, ZnT8Ab, IAA, ICA |
irAE, immune-related adverse event; APA, anti-pituitary antibody; IAD, isolated adrenocorticotropic hormone (ACTH) deficiency; 21-hydroxylase Ab, autoantibody against 21-hydroxylase; TgAb, anti-thyroglobulin antibody; TPOAb, anti-thyroid peroxidase antibody; TRAb, anti-TSH receptor antibody; Anti-CaSR Ab, anti-calcium-sensing receptor antibody; GADAb, anti-glutamic acid decarboxylase antibody; IA-2Ab, anti-islet antigen 2 antibody; ZnT8Ab, anti-zinc transporter 8 antibody; IAA, insulin autoantibody; ICA, islet cell antibody. Autoantibodies detected before the initiation of immune checkpoint inhibitors; Autoantibodies detected at the onset of endocrine irAEs.